Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
19 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
13
13 articles ont été cités au moins 13fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
637
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
88
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
13
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Claude Bernard Lyon 1 · Hospices Civils de Lyon · Hôpital Louis Pradel
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension Registry
2026ArticleEuropean Respiratory Journal
Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis
2026ArticleRespiratory Medicine and Research
Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities
2025ArticleEuropean Respiratory Journal
Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting
2024ArticleRespiratory Medicine and Research
Pulmonary function test results are correlated with 6-minute walk distance, distance-saturation product, and 6-minute walk work in patients with lymphangioleiomyomatosis
2024ArticleRespiratory Medicine and Research
Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension
2024ArticlePLoS ONE
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
2024ArticleFrontiers in Medicine
Interstitial lung disease-associated pulmonary hypertension – what the future holds
2023ArticleCurrent Opinion in Pulmonary Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL LOUIS PRADEL - HCL
28 AV DOYEN LEPINE, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2021
ObjectivePatients with systemic sclerosis and both pulmonary hypertension and interstitial lung disease (SSc–PH‐ILD) generally carry a worse prognosis than patients with SSc and pulmonary arterial hypertension (SSc‐PAH) without ILD. There is no evidence of the efficacy of PAH therapies in SSc–PH‐ILD. We undertook this study to compare survival of and response to treatment in patients with SSc–PH‐ILD and those with SSc‐PAH.MethodsWe analyzed 128 patients (66 with SSc–PH‐ILD and 62 with SSc‐PAH) from 15 centers, in whom PH was diagnosed by right‐sided heart catheterization; they were prospectively included in the PH registry. All patients received PAH‐specific therapy. Computed tomography of the chest was used to confirm or exclude ILD.ResultsAt baseline, patients with SSc–PH‐ILD had less severe hemodynamic impairment than those with SSc‐PAH (pulmonary vascular resistance 5.7 Wood units versus 8.7 Wood units; P = 0.0005) and lower diffusing capacity for carbon monoxide (median 25% [interquartile range (IQR) 18%, 35%] versus 40% [IQR 31%, 51%]; P = 0.0005). Additionally, patients with SSc–PH‐ILD had increased mortality (8.1% at 1 year, 21.2% at 2 years, and 41.5% at 3 years) compared to those with SSc‐PAH (4.1%, 8.7%, and 21.4%, respectively; P = 0.04). Upon treatment with PAH‐targeted therapy, no improvement in the 6‐minute walk distance was observed in either group. Improvement in the World Health Organization functional class was observed less frequently in patients with SSc–ILD‐PH compared to those with SSc‐PAH (13.6% versus 33.3%; P = 0.02). Hemodynamics improved similarly in both groups.ConclusionILD confers a worse prognosis to SSc‐PH. Response to PAH‐specific therapy is clinically poor in SSc–PH‐ILD but was not found to be hemodynamically different from the response observed in SSc‐PAH.
American journal of nephrology · 2018
<b><i>Background:</i></b> Pulmonary arterial hypertension (PAH) may lead to right heart failure and subsequently alter glomerular filtration rates (GFR). Chronic kidney disease (CKD, GFR &#x3c;60 mL/min/1.73 m<sup>2</sup>) may also adversely affect PAH prognosis. This study aimed to assess how right heart hemodynamics was associated with reduced estimated GFR (eGFR) and the association of CKD with survival in PAH patients. <b><i>Methods:</i></b> In a prospective PAH cohort (2003–2012), invasive hemodynamics and eGFR were collected at diagnosis (179 patients) and during follow-up (159 patients). The prevalence of CKD was assessed at PAH diagnosis. Variables, including hemodynamics, associated with reduced eGFR at diagnosis and during follow-up were tested in multivariate analysis. The association of CKD with survival was evaluated using a multivariate Cox regression model. <b><i>Results:</i></b> At diagnosis, mean age was 60.4 ± 16.5 years, mean pulmonary arterial pressure was 43 ± 12 mm Hg, and eGFR was 74.4 ± 26.4 mL/min/1.73 m<sup>2</sup>. CKD was observed in 52 incident patients (29%). Independent determinants of reduced eGFR at diagnosis were age, systemic hypertension, and decreased cardiac index. Independent determinants of reduced eGFR during follow-up were age, female gender, PAH etiology, systemic hypertension, decreased cardiac index, and increased right atrial pressure. Age ≥60 years, female gender, NYHA 4, and CKD at diagnosis were independently associated with decreased survival. The adjusted hazards ratio for death associated with CKD was 1.81 (95% confidence interval [1.01–3.25]). <b><i>Conclusion:</i></b> CKD is frequent at PAH diagnosis and is independently associated with increased mortality. Right heart failure may induce renal hypoperfusion and congestion, and is associated with eGFR decrease.
ERJ open research · 2018
Patient age at diagnosis of pulmonary hypertension is steadily increasing. The present study sought to analyse clinical characteristics, time to diagnosis and prognosis of pulmonary hypertension in elderly and very elderly patients.A study was conducted in a French regional referral centre for pulmonary hypertension. All consecutive patients diagnosed with pre-capillary pulmonary hypertension were included and categorised according to age: <65 years (“young”), 65–74 years (“elderly”) and ≥75 years (“very elderly”).Over a 4-year period, 248 patients were included: 101 (40.7%) were young, 82 (33.1%) were elderly and 65 (26.2%) were very elderly. The median age at diagnosis among the total population was 68 years. Compared with young patients, elderly and very elderly patients had a longer time to diagnosis (7±48, 9±21 and 16±32 months, respectively; p<0.001). Patients ≥75 years also more often had group 4 pulmonary hypertension. The median overall survival was 46±1.4 months, but was only 37±4.9 months in elderly patients and 28±4.7 months in very elderly patients. Survival from the first symptoms and survival adjusted to comorbidity was similar across age groups.Patient age should be taken into account when diagnosing pulmonary hypertension as it is associated with a specific clinical profile and a worse prognosis. The difference in prognosis is likely to be related to a delay in diagnosis and a greater number of comorbidities.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Respiratory medicine and research · 2025 · Letter
Riou M, Canuet M, Hirschi S, Turquier S, et al.
Respiratory medicine and research · 2025 · Letter
Guezara S, Cottin V, Francese G, Bakloul M, et al.
Journal of thoracic disease · 2025 · Journal Article
Duponchelle L, Kovacs E, Gamondes D, Drevet G, et al.
Respiratory medicine and research · 2024 · Journal Article
Boucly A, Bertoletti L, Fauvel C, Dewavrin MG, et al.
Respiratory medicine and research · 2024 · Journal Article
Diesler R, Cottin V, Gallien Y, Turquier S, et al.
Frontiers in medicine · 2024 · Journal Article
Desaintjean C, Ahmad K, Traclet J, Gerfaud-Valentin M, et al.
Respiratory medicine and research · 2023 · Review
Provost M, Mornex JF, Nasser M, Zeghmar S, et al.
Current opinion in pulmonary medicine · 2023 · Review
Cottin V, Diesler R, Turquier S, Valenzuela C
Respiratory medicine and research · 2023 · Practice Guideline
Cottin V, Blanchard E, Kerjouan M, Lazor R, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2021 · Journal Article
Chauvelot L, Gamondes D, Berthiller J, Nieves A, et al.
American journal of nephrology · 2018 · Journal Article
Bitker L, Sens F, Payet C, Turquier S, et al.
The European respiratory journal · 2026 · Journal Article
Diesler R, Turquier S, Reynaud-Gaubert M, Lestelle F, et al.
Journal of the American College of Cardiology · 2025 · Journal Article
Bertoletti L, Escal J, Boucly A, Turquier S, et al.
ERJ open research · 2018 · Journal Article
Ginoux M, Turquier S, Chebib N, Glerant JC, et al.
Pulmonary circulation · 2018 · Journal Article
Ginoux M, Cottin V, Glérant JC, Traclet J, et al.
Respiration; international review of thoracic diseases · 2020 · Journal Article
Aussedat PH, Chebib N, Ahmad K, Glerant JC, et al.
Respiration; international review of thoracic diseases · 2015 · Journal Article
Girard A, Jouneau S, Chabanne C, Khouatra C, et al.
Journal of clinical medicine · 2025 · Journal Article
Petitgrand L, Ahmad K, Gamondès D, Diesler R, et al.
Respiratory medicine and research · 2026 · Journal Article
Cottin V, Crestani B, Planès C, Chambellan A, et al.
Pulmonary circulation · 2018 · Journal Article
Ginoux M, Cottin V, Glérant JC, Traclet J, et al.
Journal of the American College of Cardiology · 2025 · Journal Article
Bertoletti L, Escal J, Boucly A, Turquier S, et al.